Atlas Trials

A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.

Clinical trial NCT05322577 · TERMINATED

Trial details

NCT number
NCT05322577
Sponsor
Amgen
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Gastric CancerGastroesophageal Junction Cancer
Start date
2022-05-17
Primary completion
2025-11-21
Enrollment
72

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.